作者
Dalia Baršytė-Lovejoy,Fengling Li,Menno J. Oudhoff,John Tatlock,Aiping Dong,Hong Zeng,Hong Wu,Spencer A. Freeman,Matthieu Schapira,Guillermo Senisterra,Ekaterina Kuznetsova,Richard Marcellus,Abdellah Allali‐Hassani,Sidney H. Kennedy,Jean‐Philippe Lambert,Amber L. Couzens,Ahmed Aman,Anne‐Claude Gingras,Rima Al‐awar,Paul V. Fish,Brian S. Gerstenberger,Lee R. Roberts,Caroline Benn,Rachel L. Grimley,Mitchell J.S. Braam,Fábio Rossi,Marius Sudol,Peter J. Brown,Mark E. Bunnage,Dafydd R. Owen,Colby Zaph,Masoud Vedadi,C.H. Arrowsmith
摘要
Significance Protein methyltransferases constitute an emerging but undercharacterized class of therapeutic targets with diverse roles in normal human biology and disease. Small-molecule “chemical probes” can be powerful tools for the functional characterization of such enzymes, and here we report the discovery of ( R )-PFI-2—a first-in-class, potent, highly selective, and cell-active inhibitor of the methyltransferase activity of SETD7 [SET domain containing (lysine methyltransferase) 7]—and two related compounds for control and chemoproteomics studies. We used these compounds to characterize the role of SETD7 in signaling, in the Hippo pathway, that controls cell growth and organ size. Our work establishes a chemical biology tool kit for the study of the diverse roles of SETD7 in cells and further validates protein methyltransferases as a druggable target class.